Alnylam Pharmaceuticals Appoints Robert Millman as Chief Patent Counsel

Sep 13,2004

Alnylam Pharmaceuticals Appoints Robert Millman as Chief Patent Counsel

CAMBRIDGE, Mass., Sept. 13 /PRNewswire-FirstCall/ -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading therapeutic RNA interference (RNAi) company, today announced the appointment of Robert Millman as Chief Patent Counsel. Mr. Millman has over 25 years of experience in the biotechnology sector, and he has served as a consultant for Alnylam since June 2003.

In his position at Alnylam, Mr. Millman will be responsible for directing all aspects of the company's intellectual property activities, and will be a member of the company's management team.

"We are delighted to formally welcome Robert to our team," commented Barry Greene, Chief Operating Officer of Alnylam. "He has demonstrated leadership and keen insight in shaping our significant IP estate for RNAi therapeutics, and his wealth of experience in developing and executing IP strategy will be invaluable as we continue to strengthen and build our patent position."

Mr. Millman has over 15 years of experience creating and managing intellectual property and patent estates for biotechnology companies. Most recently, he was a freelance intellectual property consultant for biotechnology companies and served as the Interim Chief Patent Counsel at Infinity Pharmaceuticals, Inc. From 1999 to 2002, Mr. Millman was Chief IP Counsel at Celera Genomics, where he oversaw the development and implementation of IP protection plans to secure asset value. Previously, Mr. Millman served as Patent Counsel at Millennium Pharmaceuticals, Inc. Earlier in his career, he held an associate position at Morrison and Foerster LLP. Mr. Millman received his J.D. degree from the Washington College of Law at The American University. He obtained an M.S. degree in Genetics from Washington State University and a B.S. degree in Biochemistry from the University of California, Riverside.

"I am extremely excited to be working in the field of RNAi, an area where intellectual property will be an important component of the business strategy, and I look forward to working with the management team to build on Alnylam's strong foundation in RNAi," stated Mr. Millman. "I have been impressed with the company's commitment to build a pipeline of RNAi therapeutics and their business strategy aimed at creating value from their intellectual property estate."

About RNAi
RNA interference, or RNAi, is a naturally-occurring mechanism within cells for selectively silencing and regulating specific genes that is potentially the basis for a new class of therapeutic products. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence and regulate such genes selectively through RNAi could provide a means to treat a wide range of human diseases. The discovery of RNAi has been heralded by many as a major breakthrough, and the journal Science named RNAi the top scientific achievement of 2002, as well as one of the top ten scientific advances of 2003.

About Alnylam
Alnylam is a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on RNA interference, or RNAi. Growing from its foundation as the world's first company focused on RNAi therapeutics, the company's leadership in the field of RNAi is supported by its preeminent founders and advisors and its strengths in fundamental patents, technology, and know-how that underlie the commercialization of RNAi therapeutics. Alnylam is developing a pipeline of RNAi products using Direct RNAi™ to treat ocular, central nervous system, and respiratory diseases and Systemic RNAi™ to treat a broad range of diseases, including oncologic, metabolic, and autoimmune diseases. The company's global headquarters are in Cambridge, Massachusetts. For additional information, please visit

Forward-Looking Statements
Various statements in this release concerning our future expectations, plans and prospects, including statements regarding our ability to commercialize RNAi therapeutics, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to marketable products; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales and distribution of our products; the successful development of products, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to ours and others developing products for similar uses; obtaining, maintaining and protecting intellectual property utilized by our products; and our short operating history; as well as those risks more fully discussed in the "Certain Factors That May Affect Future Results" section of our Form 10-Q filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We do not assume any obligation to update any forward-looking statements.

SORCE Alnylam Pharmaceuticals, Inc.

Investors - Lilian Stern of Stern Investor Relations, Inc.,
+1-212-362-1200; or Media - Kathryn Morris of KMorrisPR, +1-845-635-9828, both
for Alnylam Pharmaceuticals, Inc.
Web site: